Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701551 | 0.83 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2KDM1A | |
| SCHEMBL3132000 | 0.81 | SLC6A4 (0.64) | SLC6A4MEN1KMT2ASLC6A3SLC6A2 | |
| SCHEMBL26921654 | 0.81 | SLC6A4 (0.97) | SLC6A4SLC6A3SLC6A2KDM1A | |
| SCHEMBL7898287 | 0.81 | SLC6A4 (0.91) | SLC6A4SLC6A3SLC6A2KDM1A | |
| SCHEMBL2702948 | 0.80 | SLC6A4 (0.62) | SLC6A4MEN1KMT2ASLC6A3SLC6A2 | |
| SCHEMBL3520513 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2KDM1A | |
| SCHEMBL2701835 | 0.79 | MAOA (0.61) | SLC6A4KMT2ASLC6A3SLC6A2TACR1 | |
| SCHEMBL2701748 | 0.79 | CHRNA7 (0.49) | SLC6A4CHRNA7MEN1KMT2AKDM1A | |
| SCHEMBL14660868 | 0.78 | CHRNA7 (0.51) | SLC6A4CHRNA7MEN1KMT2AKDM1A | |
| SCHEMBL2834848 | 0.78 | SLC6A4 (0.62) | SLC6A4TACR1OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | SLC6A4 2532/4885CHRNA7 183/4885MEN1 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.